Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and me
(Financial Post, 2025-11-21T17:08:56Z)